MGR Foamtex has announced that its advanced anti-microbial MGRSafeWall product protection system has been successfully tested against SARS-CoV-2, the virus that causes Covid-19.
MGRSafeWall uses the latest Biomaster silver-ion technology. Laboratory testing to ISO 18184 protocols using MGRSafeWall and real aircraft cabin products has demonstrated efficacy of 96.8% against SARS-CoV-2.
The ability to complete commercial testing with SARS-CoV-2 is a very recent development as testing with the actual virus was previously only permitted in government facilities. Until now, all testing used a substitute envelope virus. The MGRSafeWall testing has been completed in Europe at one of the select specialist facilities now able to handle the virus.
MGRSafeWall has shown excellent behaviour in flammability, abrasion and resistance to cleaning agent tests. Biomaster testing has shown it is effective against a wide range of viral, bacterial and fungal threats. MGRSafeWall is, therefore, not just a powerful tool for the current pandemic but is also an investment for the future that will deliver enhanced hygiene and improved customer experience in the long term.
“This is truly exciting news for all of us in the industry. It is a real game-changer as we believe that this is the first time that real aircraft cabin materials have been tested with actual SARS-CoV-2. MGRSafeWall really is a great product for the current environment and will also keep giving value in the future,” said Jon Rose, managing director of MGR Foamtex.
Available immediately, MGRSafeWall™ can be used on both porous and non-porous cabin surfaces, either for new production or as an in-service treatment.
